KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Deffered Revenue (2020 - 2025)

AbCellera Biologics filings provide 6 years of Non-Current Deffered Revenue readings, the most recent being $5.8 million for Q3 2025.

  • Quarterly Non-Current Deffered Revenue fell 27.78% to $5.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Sep 2025, down 27.78% year-over-year, with the annual reading at $5.7 million for FY2024, 30.45% down from the prior year.
  • Non-Current Deffered Revenue hit $5.8 million in Q3 2025 for AbCellera Biologics, down from $11.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $64.8 million in Q2 2022 and bottomed at $5.7 million in Q4 2024.
  • Average Non-Current Deffered Revenue over 5 years is $27.0 million, with a median of $19.5 million recorded in 2022.
  • The largest annual shift saw Non-Current Deffered Revenue soared 123.29% in 2022 before it plummeted 73.66% in 2023.
  • AbCellera Biologics' Non-Current Deffered Revenue stood at $27.4 million in 2021, then dropped by 28.8% to $19.5 million in 2022, then plummeted by 58.01% to $8.2 million in 2023, then tumbled by 30.45% to $5.7 million in 2024, then increased by 2.63% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Non-Current Deffered Revenue are $5.8 million (Q3 2025), $11.6 million (Q2 2025), and $13.8 million (Q1 2025).